IDEMIA
15.10.2018 16:55:43 CEST | Business Wire | Press release
The supervisory board of IDEMIA, the global leader in Augmented Identity, has appointed Yann Delabrière to be Chief Executive Officer with immediate effect taking over from Didier Lamouche who has resigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005635/en/
One year after the successful coming together of Oberthur Technologies (OT) and Safran I&S (Morpho) that gave rise to IDEMIA, Yann Delabrière will be charged with overseeing a new phase in the Group’s growth.
Yann Delabrière, who previously served as CEO of Faurecia followed by CEO of Zodiac Aerospace, was appointed IDEMIA’s supervisory board chairman in January 2018. Since then he has gained in-depth understanding of the Company’s operations and people. IDEMIA will now look to benefit from Yann’s extensive international managerial experience.
Yann Delabrière stated: “I am delighted that the Supervisory Board is entrusting me with this new role, and am excited to be leading IDEMIA as it enters the next phase of its development. IDEMIA has developed cutting-edge technologies and services leveraging artificial intelligence, biometrics and cryptography. This makes IDEMIA a major technological player in the fields of identity management and authentication or security of payments. I have witnessed IDEMIA’s growth potential first hand and believe it is excellently poised to continue to consolidate its position as the leader in the sector”
Didier Lamouche added: “During almost six years at the helm of Oberthur Technologies (OT) then IDEMIA, I am extremely proud to have contributed to building, with the teams, what has become the global leader of Augmented Identity. Together, we achieved numerous commercial successes and brought to market significant innovations, not only in the financial sector, but also with access solutions combining biometrics and remote secure communication. The successful integration of both companies, OT and Morpho, fueled by solid operational results, opens a bright future to IDEMIA and all its employees. I wish them all every success.”
Notes to Editors
About Yann Delabrière
Yann Delabrière is a graduate of the Ecole
Normale Supérieure, the Ecole Nationale d’Administration (the French
National School of Administration) and has a post-graduate degree in
mathematics. He began his career at the Committee of Public Accounts
before working in the cabinet office of the Foreign Trade Ministry. He
then worked as Financial Director of COFACE (Compagnie Française
d’Assurance pour le Commerce Extérieur, a French export credit agency)
and for the Printemps Group. In 1990, he joined the PSA Peugeot Citroën
Group as Chief Financial Officer and, in this role, became a member of
the automaker’s Executive Committee in 1998, and Chairman and CEO of the
Group’s consumer finance unit, Banque PSA Finance. Yann Delabrière was
appointed as Chairman and Chief Executive Officer of Faurecia in 2007.
He was also Chairman of the Executive Board of Zodiac Aerospace between
June 2017 and February 2018. He has been a member of the Board of
Directors of Cap Gemini from 2004 to May 2018, a member of the Board of
Directors of Société Générale from 2012 to 2016, and member of the Board
of Directors of Alstom since March 2017. He has headed IDEMIA’s
Supervisory Board since January 2018.
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to provide a secure environment enabling citizens and
consumers alike to perform their daily critical activities (such as pay,
connect, travel and vote), in the physical as well as digital space.
Securing
our identity has become mission critical in the world we live in today.
By standing for Augmented Identity, we reinvent the way we think,
produce, use and protect this asset, whether for individuals or for
objects. We ensure privacy and trust as well as guarantee secure,
authenticated and verifiable transactions for international clients from
Financial, Telecom, Identity, Public Security and IoT sectors.
OT
(Oberthur Technologies) and Safran Identity & Security (Morpho) have
joined forces to form IDEMIA. With close to $3 billion in revenues and
14,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005635/en/
Contact:
IDEMIA Press Hanna Sebbah: idemia@havas.com +33 (0)6 63 73 30 30
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom